Houston Psychoanalytic Society
Clinical Conference
|
|
Trauma, Psychedelics, and Psychoanalysis
Part Two
Presented by Psychoanalysts
Megan Rundel, PhD & Karen Peoples, PhD
|
|
Saturday, September 23, 2023
10:00AM - 4:15PM Central Time
(includes one 15-min. break & 1-hr. lunch)
Live via Zoom
*Pre-Registration required for Zoom invitation
The conference will not be recorded
5 CME/CEU/CE Credits
Registration Fees
HPS Full Members: $150
HPS Student Members: $75
Non-Members: $175
Instructional Level: Intermediate
|
|
|
Ketamine and Trauma On the Couch
Megan Rundel, PhD
In this interactive presentation, we will explore the biological and psychological effects of ketamine on mental health issues, with a special focus on trauma. We will learn about how to carefully and effectively utilize the power of ketamine for patients with different kinds of trauma. Our focus will be on a psychoanalytic understanding of the ketamine experience, as well as practical information on working with this medicine in our own practices.
|
|
MDMA and Psychoanalytic Practice: A Fortuitous Alliance
Karen Peoples, PhD
Within the broad category of psychedelic drugs, MDMA is considered an "entactogen" for the openness and psychological contact it facilitates within an individual and their internal world. MDMA also enhances relational contact between the individual and others. MDMA releases neurotransmitters and and other chemicals in the brain, creating a sense of physiological ease and safety while facilitating connections between memories, emotions and higher cortical functions. Clinical research trials in carefully contained settings have shown MDMA-Assisted Therapy (MAT) to substantially reduce PTSD symptoms in a significant number of participants. With the anticipated FDA approval of MDMA for use by qualified professionals, psychoanalytic practitioners will likely see increased interest in MDMA therapy among their patients. Clinicians will benefit from an informed perspective on the protocol and clinical process of MDMA-Assisted Therapy. Similarly, psychoanalytic perspectives have much to offer the burgeoning field of MDMA-Assisted treatment. In this presentation, the topics above will be elaborated on, and the therapeutic value of non-ordinary states will be highlighted from a psychoanalytic perspective. The presentation will include interactive discussion on transference and countertransference in referrals to MAT, as well as risks and contraindications of MAT.
|
|
OBJECTIVES
After attending the program in its entirety, attendees will be able to:
- describe the mechanism of action of ketamine, methods of administration, and efficacy in treating mental health disorders.
- understand the use of ketamine through a psychoanalytic lens, including altered states of consciousness, relational issues, and the process of transformation.
- list ways that psychoanalysts can skillfully make use of ketamine treatment with patients with a history of trauma.
- identify some of the unique subjective effects of MDMA and how how these effects facilitate the treatment of severe trauma.
- assess when MDMA-Assisted Therapy (MAT) may be a useful adjunct to analytic therapy and identify contraindications to the use of MAT with patients/clients.
|
|
REFERENCES
2) Halstead, M., Reed, S., Krause, R. & Williams, M. (2021). Ketamine-assisted psychotherapy for PTSD related to racial discrimination. Clinical Case Studies, 20(4), 310-330. DOI: 10.1177/1534650121990894
3) Liriano, F., Hatten, C., & Schwartz, T. L. (2019). Ketamine as treatment for post-traumatic stress disorder: A review. Drugs in context, 8, 212305. DOI: 10.7573/dic.212305
4) Mitchell, J., et al. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27, 1025–1033
5) Ross, C., Jain, R., Bonnett, C. J., & Wolfson, P. (2019). High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Annals of Clinical Psychiatry, 31(4), 271-279.
|
|
Additional Readings:
1) Schenberg, E. E. (2018). Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Frontiers in Pharmacology: 9: 733. Published online 2018 Jul 5. https://doi.org/10.3389/fphar.2018.00733
IMAGES Image of dreamer from Can Stock; photo of Freud's office from Alamy
|
|
Megan Rundel, PhD is on the faculty, and is a Personal and Supervising Analyst, at the Psychoanalytic Institute of Northern California (PINC) in San Francisco. She is also a graduate of the Psychedelic-Assisted Therapy and Research program at California Institute of Integral Studies (CIIS) in San Francisco. She offers psychedelic psychoanalysis and psychotherapy at her office in Oakland. Her most recent publication is "Psychedelic Psychoanalysis: Transformations of the Self" in Psychoanalytic Dialogues, 2022.
|
|
Karen Peoples, PhD is a Personal/Supervising Analyst and Faculty at PINC, and Faculty at the San Francisco Center for Psychoanalysis. She served as a Sub-Investigator and Therapist on the Multidisciplinary Association for Psychedelic Studies (MAPS) Phase 3 clinical trial for treatment-resistant PTSD at the University of California, San Francisco, and is currently a Consultant for MAPS' European Clinical Trials of MDMA-Assisted Therapy for PTSD. She is in private practice in the San Francisco Bay area. Karen was formerly Associate Professor of Doctoral Psychology at the CIIS. She has published and presented numerous analytic papers on uncanny forms of unconscious communication, incest trauma, transcendent forms of emptiness, social trauma, and unconscious bodily communication. In 2021 she presented an individual paper on psychoanalysis and non-ordinary states of consciousness, and a panel presentation on psychoanalysis and psychedelic-assisted therapy at the International Psychoanalytic Association’s Bi-Annual Congress. Her latest publication, "The Mystery of the Unconscious: Integrating Non-Ordinary States in Psychedelic-Assisted Therapy," is a chapter in Integral Psychedelic Therapy: The Non-Ordinary Art of Psychospiritual Healing, to be published by Routledge in June 2023. Karen has a long-standing interest in contemplative traditions and practices.
|
|
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American Psychoanalytic Association and Houston Psychoanalytic Society. The American Psychoanalytic Association is accredited by the ACCME to provide continuing medical education for physicians.
The American Psychoanalytic Association designates this Live Activity for a maximum of 5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
IMPORTANT DISCLOSURE INFORMATION FOR ALL LEARNERS: None of the planners and presenters for this educational activity have relevant financial relationship(s)* to disclose with ineligible companies* whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
*Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.
-Updated July 2021-
|
|
Houston Psychoanalytic Society is approved by the American Psychological Association to sponsor continuing education for psychologists. Houston Psychoanalytic Society maintains responsibility for this program and its content.
HPS, through co-sponsorship with the Center for Psychoanalytic Studies, also offers approved CEUs for Texas state-approved social workers, licensed professional counselors, and marriage and family therapists.
|
|
1302 Waugh Dr. #276, Houston, TX 77019
(713) 429-5810
|
|
|
|
|
|
|
